Aptevo Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
APVO Nasdaq 2830 aptevotherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aptevo Therapeutics Inc.

Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025 - Dec 9th, 2025 6:05 am
Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Nov 19th, 2025 7:55 am
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors - Nov 10th, 2025 6:05 am
Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update - Nov 6th, 2025 6:05 am
Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter - Oct 8th, 2025 6:20 am
Wall Street Set to Open Higher Thursday; Jobless Claims Fall as Manufacturing Index Rebounds - Sep 18th, 2025 7:27 am
Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML - Sep 16th, 2025 6:30 am
Foremost Clean Energy and Aptevo Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Sep 5th, 2025 7:00 am
Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules - Sep 4th, 2025 6:45 am
Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer - Aug 13th, 2025 6:05 am
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update - Aug 11th, 2025 6:05 am
Aptevo Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Aug 8th, 2025 7:00 am
Aptevo Meets Nasdaq $2.5M Equity Requirement - Jul 15th, 2025 2:57 pm
Aptevo announces addition of preclinical candidate APVO455 to portfolio - Jun 21st, 2025 7:00 am
Aptevo Therapeutics Launches $8 Million Offering - Jun 18th, 2025 9:35 am
Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules - Jun 18th, 2025 8:52 am
Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML - Jun 18th, 2025 6:01 am
Aptevo Participating in the BIO International Convention - Jun 13th, 2025 6:05 am
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan - May 22nd, 2025 6:05 am
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig - May 15th, 2025 6:05 am